ArticleOncotarget2012

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.

Ophélie Cassuto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.